SG11201909562PA - Treatment of a bacterial vaginal infection - Google Patents
Treatment of a bacterial vaginal infectionInfo
- Publication number
- SG11201909562PA SG11201909562PA SG11201909562PA SG11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA SG 11201909562P A SG11201909562P A SG 11201909562PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vaginal infection
- pct
- treatment
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo OH imiononoiliflo oimIE (10) International Publication Number WO 2018/188992 Al (51) International Patent Classification: A61K 31/4178 (2006.01) A61K 9/00 (2006.01) A61K 31/4164 (2006.01) A61K 9/20 (2006.01) A61K 31/7048 (2006.01) A61K 47/06 (2006.01) A61K 45/06 (2006.01) A61P 31/04 (2006.01) (21) International Application Number: Published: — with international search report (Art. 21(3)) PCT/EP2018/058508 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17461524.5 14 April 2017 (14.04.2017) EP (71) Applicant: ADAMED PHARMA S.A. [PL/PL]; Pienkow, ul. Mariana Adamkiewicza 6A, 05-152 Czosnow (PL). (72) Inventors: BERDZIK-KALARUS, Sylwia; ul. Czajek 14, 40-534 Katowice (PL). SULIKOWSKI, Daniel; ul. Oby- watelska 34, 02-409 Warszawa (PL). (74) Agent: SULIKOWSKI, Daniel; ADMARKA SP. Z 0.0., Pienkow 149, 05-152 Czosnow (PL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.170) 0\ 00 00 1-1 (54) Title: TREATMENT OF A BACTERIAL VAGINAL INFECTION O (57) : The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria. O
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17461524.5A EP3388063A1 (en) | 2017-04-14 | 2017-04-14 | Treatment of a bacterial vaginal infection |
PCT/EP2018/058508 WO2018188992A1 (en) | 2017-04-14 | 2018-04-03 | Treatment of a bacterial vaginal infection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909562PA true SG11201909562PA (en) | 2019-11-28 |
Family
ID=58578922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909562P SG11201909562PA (en) | 2017-04-14 | 2018-04-03 | Treatment of a bacterial vaginal infection |
Country Status (18)
Country | Link |
---|---|
US (2) | US11684608B2 (en) |
EP (2) | EP3388063A1 (en) |
BR (1) | BR112019021404A2 (en) |
CO (1) | CO2019011305A2 (en) |
CR (1) | CR20190466A (en) |
DK (1) | DK3609493T3 (en) |
EA (1) | EA201992448A1 (en) |
ES (1) | ES2984250T3 (en) |
FI (1) | FI3609493T3 (en) |
LT (1) | LT3609493T (en) |
MX (1) | MX2019012232A (en) |
MY (1) | MY196293A (en) |
PH (1) | PH12019502332A1 (en) |
PL (1) | PL3609493T3 (en) |
PT (1) | PT3609493T (en) |
RS (1) | RS65819B1 (en) |
SG (1) | SG11201909562PA (en) |
WO (1) | WO2018188992A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3388063A1 (en) * | 2017-04-14 | 2018-10-17 | Adamed sp. z o.o. | Treatment of a bacterial vaginal infection |
US11529346B2 (en) * | 2020-06-18 | 2022-12-20 | National Medical Supply, LLC | Vaginal gel |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500516A (en) * | 1982-10-22 | 1985-02-19 | Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr | Antibacterial pharmaceutical composition |
US4542020A (en) * | 1984-08-17 | 1985-09-17 | E. R. Squibb & Sons, Inc. | Long-lasting adhesive antifungal suppositories |
CA2008775C (en) | 1989-02-24 | 1998-12-22 | Alberto Ferro | Nail lacquer |
WO2002014493A2 (en) * | 2000-08-11 | 2002-02-21 | Whitehead Institute For Biomedical Research | Control of biofilm development |
JP2004067599A (en) * | 2002-08-07 | 2004-03-04 | Kunihiko Tominaga | In-vagina detergent |
WO2012106264A2 (en) * | 2011-01-31 | 2012-08-09 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections |
EP3388063A1 (en) | 2017-04-14 | 2018-10-17 | Adamed sp. z o.o. | Treatment of a bacterial vaginal infection |
-
2017
- 2017-04-14 EP EP17461524.5A patent/EP3388063A1/en not_active Withdrawn
-
2018
- 2018-04-03 EP EP18716578.2A patent/EP3609493B1/en active Active
- 2018-04-03 RS RS20240879A patent/RS65819B1/en unknown
- 2018-04-03 DK DK18716578.2T patent/DK3609493T3/en active
- 2018-04-03 EA EA201992448A patent/EA201992448A1/en unknown
- 2018-04-03 MX MX2019012232A patent/MX2019012232A/en unknown
- 2018-04-03 WO PCT/EP2018/058508 patent/WO2018188992A1/en active Application Filing
- 2018-04-03 CR CR20190466A patent/CR20190466A/en unknown
- 2018-04-03 LT LTEPPCT/EP2018/058508T patent/LT3609493T/en unknown
- 2018-04-03 BR BR112019021404A patent/BR112019021404A2/en unknown
- 2018-04-03 PL PL18716578.2T patent/PL3609493T3/en unknown
- 2018-04-03 SG SG11201909562P patent/SG11201909562PA/en unknown
- 2018-04-03 MY MYPI2019005956A patent/MY196293A/en unknown
- 2018-04-03 US US16/604,850 patent/US11684608B2/en active Active
- 2018-04-03 ES ES18716578T patent/ES2984250T3/en active Active
- 2018-04-03 PT PT187165782T patent/PT3609493T/en unknown
- 2018-04-03 FI FIEP18716578.2T patent/FI3609493T3/en active
-
2019
- 2019-10-11 CO CO2019011305A patent/CO2019011305A2/en unknown
- 2019-10-11 PH PH12019502332A patent/PH12019502332A1/en unknown
-
2023
- 2023-05-08 US US18/313,671 patent/US20230270725A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2984250T3 (en) | 2024-10-29 |
EP3609493B1 (en) | 2024-05-15 |
EP3388063A1 (en) | 2018-10-17 |
BR112019021404A2 (en) | 2020-04-28 |
PL3609493T3 (en) | 2024-09-02 |
EA201992448A1 (en) | 2020-02-17 |
WO2018188992A1 (en) | 2018-10-18 |
US20200078337A1 (en) | 2020-03-12 |
EP3609493A1 (en) | 2020-02-19 |
RS65819B1 (en) | 2024-09-30 |
CO2019011305A2 (en) | 2019-10-31 |
LT3609493T (en) | 2024-08-26 |
US11684608B2 (en) | 2023-06-27 |
PH12019502332A1 (en) | 2020-10-12 |
PT3609493T (en) | 2024-08-14 |
US20230270725A1 (en) | 2023-08-31 |
MX2019012232A (en) | 2019-11-28 |
MY196293A (en) | 2023-03-24 |
DK3609493T3 (en) | 2024-08-05 |
FI3609493T3 (en) | 2024-08-13 |
CR20190466A (en) | 2019-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907034PA (en) | Methods of treating influenza | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201809341PA (en) | Mobile robot | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
SG11201810801QA (en) | Brain delivery protein | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |